Spots Global Cancer Trial Database for A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Official Title: A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)

Study ID: NCT06418412

Conditions

Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer

Interventions

Study Description

Brief Summary: There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies. This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.

Detailed Description: This study will be a multi-center observational study and will enroll patients with advanced EGFR exon 20 insertion mutated NSCLC. The study will include patients recruited from countries across Asia, including sites in, but not limited to - Hong Kong, Korea, Singapore, Taiwan and Thailand. There will be approximately 20-30 sites recruiting for the study. In Singapore, sites may include National Cancer Centre Singapore (NCCS), National University Hospital (NUH) and Tan Tock Seng Hospital (TTSH). Approximately 600 patients will be enrolled retrospectively.